PubMed
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review)
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
Compare
BPC-157 (Oral) vs Tesamorelin
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
BPC-157 (Oral)
26 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 97% · Mixed 3% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
157
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Digestive upset
4
Self-reported dose per injection
Median bucket: 0.6–1 mg · Most common: 1–2 mg
Reports span 0.2–2 mg
0.2–0.4 mg
50
0.4–0.6 mg
6
0.6–1 mg
49
1–2 mg
52
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 90% said they felt similar to their last entry, 10% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 215 days · Based on 20 repeat reporters
Tesamorelin
114 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
224
Sleep
1
Recovery
1
Libido
1
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
113
Water retention
106
Self-reported dose per injection
Median bucket: 1–2 mg · Most common: 1–2 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
9
0.1–0.2 mg
1
0.2–0.4 mg
5
0.4–0.6 mg
5
0.6–1 mg
4
1–2 mg
126
2–3 mg
74
5+ mg
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 88% said they felt similar to their last entry, 12% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 46 days · Based on 41 repeat reporters
Sources (10)
Published sources linked on the BPC-157 (Oral) and Tesamorelin wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
- Wiki study page →Source
PubMed
Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions
Ilic S, Drmic D, Franjic S, et al. Life sciences. 2011
- Wiki study page →Source
PubMed
Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions
Tlak Gajger I, Ribarić J, Smodiš Škerl M, et al. Journal of veterinary pharmacology and therapeutics. 2018
- Wiki study page →Source
FDA Drug Label
EGRIFTA (tesamorelin) for injection - Prescribing Information
Theratechnologies. FDA Drug Label. 2010
- Wiki study page →Source
PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo E, Arvat E, Camanni F. Endocrine. 2008
- Wiki study page →Source
ClinicalTrials.gov
Tesamorelin HIV lipodystrophy studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
FDA Drug Label
EGRIFTA SV (tesamorelin) for injection - Prescribing Information
Theratechnologies. FDA Drug Label. 2019
- Wiki study page →Source
PubMed
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy
Spooner LM, Olin JL. The Annals of pharmacotherapy. 2012
- Wiki study page →Source
PubMed
Tesamorelin
2018